dr hab. n. med. Agnieszka Wierzbowska
Quick facts
Marketed products
- DAC · Oncology
DAC is a cytidine deaminase inhibitor that enhances the activity of cytarabine by preventing its inactivation.
Phase 3 pipeline
- Consolidation, I HAM cycle · Oncology
The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells. - Consolidation, III HiDAraC cycle · Oncology
HiDAraC (high-dose cytarabine consolidation) is a chemotherapy regimen that delivers high doses of cytarabine to inhibit DNA synthesis and induce apoptosis in leukemic cells. - II Consolidation HiDAraC · Oncology
II Consolidation HiDAraC is a high-dose cytarabine (ara-C)-based chemotherapy regimen used as consolidation therapy in acute myeloid leukemia.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- dr hab. n. med. Agnieszka Wierzbowska portfolio CI brief
- dr hab. n. med. Agnieszka Wierzbowska pipeline updates RSS
Frequently asked questions about dr hab. n. med. Agnieszka Wierzbowska
What are dr hab. n. med. Agnieszka Wierzbowska's marketed drugs?
Top marketed products include DAC.
What is dr hab. n. med. Agnieszka Wierzbowska's pipeline?
dr hab. n. med. Agnieszka Wierzbowska has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Consolidation, I HAM cycle, Consolidation, III HiDAraC cycle, II Consolidation HiDAraC.
Related
- DAC · Oncology
- Sector hub: All tracked pharma companies